Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy

被引:509
|
作者
Eggener, Scott E. [3 ]
Scardino, Peter T. [4 ]
Walsh, Patrick C. [5 ]
Han, Misop [5 ]
Partin, Alan W. [5 ]
Trock, Bruce J. [5 ]
Feng, Zhaoyong [5 ]
Wood, David P. [6 ]
Eastham, James A. [4 ]
Yossepowitch, Ofer [7 ]
Rabah, Danny M. [8 ]
Kattan, Michael W.
Yu, Changhong [2 ]
Klein, Eric A. [1 ]
Stephenson, Andrew J. [1 ]
机构
[1] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[3] Univ Chicago, Med Ctr, Urol Sect, Chicago, IL 60637 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[5] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
[6] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[7] Rabin Med Ctr, Petah Tiqwa, Israel
[8] King Saud Univ, Dept Surg, Div Urol, Princess Johara Alibrahim Ctr Canc Res, Riyadh, Saudi Arabia
来源
JOURNAL OF UROLOGY | 2011年 / 185卷 / 03期
基金
美国国家卫生研究院;
关键词
prostate; prostatic neoplasms; prostatectomy; mortality; nomograms; BIOCHEMICAL RECURRENCE; SALVAGE RADIOTHERAPY; RADIATION-THERAPY; NATURAL-HISTORY; SURVIVAL; RISK; NOMOGRAM; OUTCOMES; TRIAL; MEN;
D O I
10.1016/j.juro.2010.10.057
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Long-term prostate cancer specific mortality after radical prostatectomy is poorly defined in the era of widespread screening. An understanding of the treated natural history of screen detected cancers and the pathological risk factors for prostate cancer specific mortality are needed for treatment decision making. Materials and Methods: Using Fine and Gray competing risk regression analysis we modeled clinical and pathological data, and followup information on 11,521 patients treated with radical prostatectomy at a total of 4 academic centers from 1987 to 2005 to predict prostate cancer specific mortality. The model was validated on 12,389 patients treated at a separate institution during the same period. Median followup in the modeling and validation cohorts was 56 and 96 months, respectively. Results: The overall 15-year prostate cancer specific mortality rate was 7%. Primary and secondary Gleason grade 4-5 (each p < 0.001), seminal vesicle invasion (p < 0.001) and surgery year (p = 0.002) were significant predictors of prostate cancer specific mortality. A nomogram predicting 15-year prostate cancer specific mortality based on standard pathological parameters was accurate and discriminating with an externally validated concordance index of 0.92. When stratified by patient age at diagnosis, the 15-year prostate cancer specific mortality rate for pathological Gleason score 6 or less, 3 + 4, 4 + 3 and 8-10 was 0.2% to 1.2%, 4.2% to 6.5%, 6.6% to 11% and 26% to 37%, respectively. The 15-year prostate cancer specific mortality risk was 0.8% to 1.5%, 2.9% to 10%, 15% to 27% and 22% to 30% for organ confined cancer, extraprostatic extension, seminal vesicle invasion and lymph node metastasis, respectively. Only 3 of 9,557 patients with organ confined, pathological Gleason score 6 or less cancer died of prostate cancer. Conclusions: Poorly differentiated cancer and seminal vesicle invasion are the prime determinants of prostate cancer specific mortality after radical prostatectomy. The prostate cancer specific mortality risk can be predicted with remarkable accuracy after the pathological features of prostate cancer are known.
引用
收藏
页码:869 / 875
页数:7
相关论文
共 50 条
  • [31] 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era EDITORIAL COMMENT
    Moul, Judd W.
    [J]. UROLOGY, 2015, 86 (04) : 788 - 788
  • [32] Re: Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
    Shteynshlyuger, Alex
    Kibel, Adam S.
    [J]. EUROPEAN UROLOGY, 2009, 56 (06) : 1089 - 1090
  • [33] Predicting survival of men with recurrent prostate cancer after radical prostatectomy
    Dell'Oglio, Paolo
    Suardi, Nazareno
    Boorjian, Stephen A.
    Fossati, Nicola
    Gandaglia, Giorgio
    Tian, Zhe
    Moschini, Marco
    Capitanio, Umberto
    Karakiewicz, Pierre I.
    Montorsi, Francesco
    Karnes, R. Jeffrey
    Briganti, Alberto
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 27 - 34
  • [34] Nomogram predicting 10 year life expectancy after radical prostatectomy or radiation therapy for prostate cancer
    Walz, Jochen
    Gallina, Andrea
    Bocciardi, Aldo M.
    Ahyal, Sascha
    Perrotte, Paul
    Mc Cormack, Michael
    Benard, Francois
    Saad, Fred
    Montorsi, Francesco
    Graefen, Markus
    Valiquette, Luc
    Karakiewicz, Pierre I.
    [J]. JOURNAL OF UROLOGY, 2007, 177 (04): : 131 - 132
  • [35] Nomogram predicting 10 year life expectancy after radical prostatectomy or radiation therapy for prostate cancer
    Walz, J.
    Gallina, A.
    Bocciardi, A.
    Ahyai, S.
    Perrotte, P.
    Mccormack, M.
    Benard, F.
    Saad, F.
    Montorsi, F.
    Graefen, M.
    Valiquette, L.
    Karakiewicz, P.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 202 - 202
  • [36] Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
    Stephenson, AJ
    Scardino, PT
    Eastham, JA
    Bianco, FJ
    Dotan, ZA
    DiBlasio, CJ
    Reuther, A
    Klein, EA
    Kattan, MW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7005 - 7012
  • [37] Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
    Stephenson, Andrew J.
    Scardino, Peter T.
    Eastham, James A.
    Bianco, Fernando J., Jr.
    Dotan, Zohar A.
    Fearn, Paul A.
    Kattan, Michael W.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) : 715 - 717
  • [38] Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy
    Chen, Michelle S.
    Howard, Lauren E.
    Stock, Shannon
    Dolgner, Anna
    Freedland, Stephen J.
    Aronson, William
    Terris, Martha
    Klaassen, Zachary
    Kane, Christopher
    Amling, Christopher
    Cooperberg, Matthew
    Daskivich, Timothy J.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (04) : 715 - 721
  • [39] Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy
    Michelle S. Chen
    Lauren E. Howard
    Shannon Stock
    Anna Dolgner
    Stephen J. Freedland
    William Aronson
    Martha Terris
    Zachary Klaassen
    Christopher Kane
    Christopher Amling
    Matthew Cooperberg
    Timothy J. Daskivich
    [J]. Prostate Cancer and Prostatic Diseases, 2023, 26 : 715 - 721
  • [40] Racial disparities in mortality for patients with prostate cancer after radical prostatectomy
    Wen, Wanqing
    Luckenbaugh, Amy N.
    Bayley, Christina E.
    Pension, David F.
    Shu, Xiao-Ou
    [J]. CANCER, 2021, 127 (09): : 1517 - 1528